of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Other Events. The Company intends to use the net proceeds from the Offering to advance its lead clinical program, MICVO, through key clinical milestones, including Headliner™, its planned Phase 3 trial in 2L+ R/M HNSCC, and for working capital and general corporate purposes. The Company currently expects that its existing cash and cash equivalents, together with the net proceeds from the Offering, will be sufficient to fund its operating expenses and capital expenditure requirements into the…

Entry Into a Material Definitive Agreement. On September 29, 2026, Pyxis Oncology, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Guggenheim Securities, LLC and Wells Fargo Securities, LLC, as representatives of the several underwriters named therein (the “Underwriters”), relating to an underwritten public offering (the “Offering”) of (i) (a) 36,047,919 shares (the “Shares”) of the Company’s common stock, par value $0.001…

Other Events. The Company today announced updated data from its ongoing global Phase 1 monotherapy study evaluating micvotabart pelidotin (MICVO) in patients with second-line and beyond (2L+) recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The cutoff date for all data reported below is August 18, 2026. Demographics Table 1: Patient Demographics and Disease Characteristics – 5.4 mg/kg Dose Cap Population (N=35) Data as of 18-Aug-2026 1. cetuximab: Eli Lilly and Company…

CEO — Thomas Civik: The appointment of the Interim CEO to the permanent CEO role is an internal promotion that provides leadership stability, not a departure.

of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Regulation FD Disclosure. On June 30, 2026, the Company issued a press release announcing the Private Placement. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information contained in this Item 7.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any…

Unregistered Sales of Equity Securities. To the extent required by Form 8-K, the disclosures in

Entry into a Material Definitive Agreement. Securities Purchase Agreement On June 30, 2026, Pyxis Oncology, Inc. (the “Company”) entered into a securities purchase agreement (the “Securities Purchase Agreement”) for a private placement (the “Private Placement”) with certain institutional and accredited investors (each, a “Purchaser” and collectively, the “Purchasers”). Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell to the Purchasers an aggregate of (i) 19,…

of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Director — Dr. Sullivan: Dr. Sullivan resigned from the Board of Directors and separated from the Company under a Separation Agreement.

Results of Operations and Financial Condition. On March 23, 2026, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the full year ended December 31, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

CEO — Dr. Lara Sullivan, M.D.: Dr. Lara Sullivan ceased serving as CEO and was replaced by Tom Civik as Interim Chief Executive Officer.

Other Events. The Company today announced positive preliminary data from its ongoing Phase 1 clinical studies evaluating micvotabart pelidotin (MICVO), a first-in-concept antibody-drug conjugate (ADC) targeting extradomain-B of fibronectin (EDB+FN), a non-cellular structural component of the tumor extracellular matrix (ECM), in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). The cutoff for all data reported below is as of November 3, 2025. Monotherapy The…

of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

of this Current Report, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing with the U.S. Securities and Exchange Commission made by the Company, regardless of any general incorporation language in such filings.

Chief Financial Officer and Chief Operating Officer — Pamela Connealy: Ms. Connealy retired from the Company and was succeeded by Jitendra Wadhane as Principal Financial Officer.

Results of Operations and Financial Condition. On May 15, 2025, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the Quarter ended March 31, 2025 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Results of Operations and Financial Condition. On March 18, 2025, Pyxis Oncology, Inc. (“the Company”) issued a press release announcing its financial results for the full year ended December 31, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Chief Medical Officer — Ken Kobayashi, M.D., F.A.C.P: Ken Kobayashi is stepping down from his position as Chief Medical Officer, and Lara S. Sullivan will assume the role in addition to her current roles.

Other Events. On February 26, 2025, Pyxis Oncology, Inc. issued a press release announcing that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) whose disease has progressed following treatment with platinum-based chemotherapy and an anti-PD-(L)1 antibody. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-…

Other Events. On February 4, 2025, Pyxis Oncology, Inc. issued a press release announcing the initiation of a Phase 1/2 combination trial, PYX-201-102, with PYX-201 and Merck’s Keytruda® (pembrolizumab) in multiple solid tumors. In addition, the Part 2 monotherapy expansion cohorts of the ongoing Phase 1 PYX-201-101 study have begun enrolling patients. A copy of this press release is attached as Exhibit 99.1 to this Current Report on Form 8-K. KEYTRUDA ® is a registered trademark of Merck Sha…

Other Events. On December 19, 2024, Pyxis Oncology, Inc. (the “Company”) announced a portfolio prioritization, focusing resources on advancing its lead clinical program, PYX-201, a first-in-concept antibody-drug conjugate (ADC) with a microtubule inhibitor (optimized auristatin) payload that uniquely targets Extradomain-B Fibronectin (EDB+FN), a non-cellular structural component within the tumor extracellular matrix. A copy of the press release is attached hereto as Exhibit 99.1 to this Curre…

Results of Operations and Financial Condition. On November 12, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended September 30, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of t…

Results of Operations and Financial Condition. On August 14, 2024, Pyxis Oncology, Inc. (the “Company”) issued a press release announcing its financial results for the quarter ended June 30, 2024 and provided a corporate update. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information contained in this Item 2.02, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Secu…